Effect of Ensifentrine Treatment on CAT Score

Summary

The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.

Timeline

Start

2024-06-11

Primary completion

2024-11-26

Completion

2024-12-03

Publications

• Siler TM, Rheault T, Reyner D, MacDonald-Berko M, Davidson J, Rickard K. Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2026 Feb 10;21:589655. doi: 10.2147/COPD.S589655. eCollection 2026.

Drugs

Indications